Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis
Shots: The first patient has been dosed in P-II CIBI112A201 clinical trial evaluating IBI112 (SC, anti-IL-23p19 mAb) in patients with moderate-to-severe PsO The primary objective of the study is to evaluate the efficacy of IBI112 at different doses. The safety of drugs & difference of administration interval b/w the different therapeutic regimens will also be […]